Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more
Cathay Biotech Inc (688065) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.23 Billion CNY
Based on the latest financial reports, Cathay Biotech Inc (688065) has total liabilities worth CN¥2.23 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cathay Biotech Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Cathay Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cathay Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Cathay Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kemira Oyj
PINK:KOYJF
|
USA | $1.44 Billion |
|
Burckhardt Compression Holding AG
LSE:0QNN
|
UK | £862.30 Million |
|
Hiab B
HE:HIAB
|
Finland | €618.20 Million |
|
G Mining Ventures Corp
OTCQX:GMINF
|
USA | $427.78 Million |
|
Banner Corporation
NASDAQ:BANR
|
USA | $14.41 Billion |
|
Zhejiang Weiming Environment Protection Co Ltd
SHG:603568
|
China | CN¥13.44 Billion |
|
AVIC Capital Co Ltd
SHG:600705
|
China | CN¥376.59 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Cathay Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cathay Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cathay Biotech Inc (2016–2024)
The table below shows the annual total liabilities of Cathay Biotech Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.92 Billion | -3.44% |
| 2023-12-31 | CN¥4.06 Billion | +45.58% |
| 2022-12-31 | CN¥2.79 Billion | +84.61% |
| 2021-12-31 | CN¥1.51 Billion | +132.16% |
| 2020-12-31 | CN¥650.74 Million | -51.43% |
| 2019-12-31 | CN¥1.34 Billion | -20.38% |
| 2018-12-31 | CN¥1.68 Billion | +79.68% |
| 2017-12-31 | CN¥936.58 Million | +113.24% |
| 2016-12-31 | CN¥439.21 Million | -- |